TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24961892

Group type: EXPERIMENTAL
Intervention: Cobalt‐chrome (CoCr) and ultra‐high molecular weight polyethylene (UHMWPE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cobalt‐chrome (CoCr) and cross-linked polyethylene (XLPE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oxinium and ultra‐high molecular weight polyethylene (UHMWPE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oxinium and cross-linked polyethylene (XLPE)
Number of subjects: 80
Study: 23770175

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 1664

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1664
Study: 19358746

Group type: EXPERIMENTAL
Intervention: Training in cognitive behaviour therapy (CBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 34
Study: 18178463

Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 10
Study: 16313107

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cisapride (Control group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Marzulene‐s granule (Control group 2)
Number of subjects: 90
Study: 12704002

Group type: EXPERIMENTAL
Intervention: Taxotere single agent (75 mg/m2 iv 1 hour)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Taxotere (60 mg/m2 iv 1 hour) plus Adriamycin (50 mg/m2 iv 1 hour)
Number of subjects: 34
Study: 10492632

Group type: EXPERIMENTAL
Intervention: 320 mg of Megestrol Acetate (MA) daily for 12 weeks
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 8740271

Group type: EXPERIMENTAL
Intervention: Concentrated essential fatty acids
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1759762

Group type: EXPERIMENTAL
Intervention: Single dose of ampicillin before insertion of the chest tube
Number of subjects: 188

Group type: COMPARATOR
Intervention: Additional antibiotic prophylaxis for as long as the drain was in place
Number of subjects: 188
Study: 6125678

Group type: EXPERIMENTAL
Intervention: Mantoux test (10 IU PPD-Weybridge)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tine test
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Imotest
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mantoux test (repeated)
Number of subjects: 200
Study: 30997917

Group type: EXPERIMENTAL
Intervention: ApoE ε4 status
Number of subjects: 1300
Study: 28634219

Group type: EXPERIMENTAL
Intervention: Intravenous high-dose N-acetylcysteine (29 g over 2 days) with low-dose nitroglycerin (7.2 mg over 2 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo with low-dose nitroglycerin
Number of subjects: 112
Study: 26648084

Group type: COMPARATOR
Intervention: Intravenous tabalumab (0.01, 0.04, 0.125, 0.5, 2.0, and 8.0 mg/kg for RA; 0.125 or 2.0 mg/kg for SLE)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subcutaneous tabalumab (20 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous tabalumab (10 mg)
Number of subjects: 41
Study: 25241196

Group type: EXPERIMENTAL
Intervention: COPD‐PS + copd‐6
Number of subjects: 8770

Group type: EXPERIMENTAL
Intervention: COPD‐PS
Number of subjects: 8770

Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 8770
Study: 21334099

Group type: EXPERIMENTAL
Intervention: Older individuals with high amyloid burden
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hippocampus activity across groups
Number of subjects: 0
Study: 19410975

Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented infant formula
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonsupplemented formula (Control)
Number of subjects: 81
Study: 17434505

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Minilaparotomic myomectomy
Number of subjects: 136
Study: 15459210

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m² every 28 days
Number of subjects: 301

Group type: COMPARATOR
Intervention: Comparator (vinorelbine 30 mg/m² weekly or mitomycin C 10 mg/m² day 1 and every 28 days plus vinblastine 5 mg/m² day 1, day 14, day 28, and day 42)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: PLD in anthracycline-naïve patients
Number of subjects: 301

Group type: COMPARATOR
Intervention: Comparator in anthracycline-naïve patients
Number of subjects: 301
Study: 11448376

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg/d) + Clonazepam (0.5 mg, 3 times daily for 4 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sertraline (100 mg/d) + Placebo Clonazepam
Number of subjects: 50
Study: 9602960

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tramadol (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7927548

Group type: COMPARATOR
Intervention: Normotensive pregnant women
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Women with pregnancy induced hypertension (PIH)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normotensive pregnant women and women with PIH
Number of subjects: 105
Study: 2682431

Group type: EXPERIMENTAL
Intervention: oxpentifylline (Hoechst UK)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 1096595

Group type: EXPERIMENTAL
Intervention: Fluoride-vitamin supplement from infancy
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Fluoridated water
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Fluoride-vitamin supplement from age 4
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1500
Study: 31924258

Group type: EXPERIMENTAL
Intervention: Participatory driven web-application
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard website
Number of subjects: 20
Study: 29788253

Group type: EXPERIMENTAL
Intervention: e‐Exercise (3-month intervention with about 5 face-to-face physical therapy sessions integrated with an online application)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual physical therapy (conducted according to Dutch physical therapy guidelines)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: e‐Exercise
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: e‐Exercise and Usual physical therapy
Number of subjects: 208
Study: 26249791

Group type: EXPERIMENTAL
Intervention: RISTOMED diet
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: RISTOMED diet plus AISA d‐Limonene
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: RISTOMED diet plus VSL#3 probiotic blend
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: RISTOMED diet with AISA d‐Limonene supplementation
Number of subjects: 125
Study: 24560487

Group type: EXPERIMENTAL
Intervention: BIRIP (irinotecan 60mg/m² plus cisplatin 30mg/m², every 2 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: irinotecan alone (irinotecan 150mg/m², every 2 weeks)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: BIRIP
Number of subjects: 130

Group type: COMPARATOR
Intervention: irinotecan alone
Number of subjects: 130
Study: 22251035

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium hydroxide cement (Dycal(®))
Number of subjects: 60
Study: 20951321

Group type: EXPERIMENTAL
Intervention: Corticosteroids (intravenous hydrocortisone 2 mg/kg on the day of procedure and oral prednisolone 0.5 mg/kg/day for 3 days after PVI)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 125
Study: 17692385

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 15452804

Group type: EXPERIMENTAL
Intervention: Steroid treatment starting at 3 weeks post-surgery
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Steroid treatment starting at 6 weeks post-surgery
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Steroid treatment starting at 1 week post-surgery
Number of subjects: 27

Group type: COMPARATOR
Intervention: No steroid treatment (NST)
Number of subjects: 27
Study: 11420164

Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon counterpulsation therapy (IABP)
Number of subjects: 0
Study: 9679847

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Montelukast 100 mg once daily
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Montelukast 200 mg once daily
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg twice daily
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Montelukast 50 mg twice daily
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 7862791

Group type: EXPERIMENTAL
Intervention: Adult Form of Coopersmith's Self‐esteem Inventory
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TestWell (revised wellness inventory)
Number of subjects: 90
Study: 2492252

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vasopressin + nitroglycerin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 50
Study: 16324164

Group type: EXPERIMENTAL
Intervention: Tramadol/APAP (75 mg/650 mg)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 30052579

Group type: EXPERIMENTAL
Intervention: Heating Challenge (HC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combination of Pc-aCO2 >17 mm Hg with positive ΔPcCO2
Number of subjects: 59
Study: 29141365

Group type: EXPERIMENTAL
Intervention: Short-acting combined oral contraceptives
Number of subjects: 726
Study: 24621661

Group type: EXPERIMENTAL
Intervention: Full intervention programme (Group A)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Partial intervention (Group B)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 204
Study: 23789934

Group type: EXPERIMENTAL
Intervention: Raisins
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Grapes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Potato Chips
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cookies
Number of subjects: 26
Study: 22117718

Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite (G1) for 1 min
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite (G1) for 10 min
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (G2) for 1 min
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (G2) for 10 min
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (G3) for 1 min
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (G3) for 10 min
Number of subjects: 86

Group type: COMPARATOR
Intervention: 0.9% saline solution (G4) for 1 min
Number of subjects: 86

Group type: COMPARATOR
Intervention: 0.9% saline solution (G4) for 10 min
Number of subjects: 86
Study: 18608543

Group type: EXPERIMENTAL
Intervention: Diet C (increased consumption of breakfast cereals)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Diet V (increased consumption of vegetables)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both Diet C and Diet V
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Diet C
Number of subjects: 57
Study: 16783667

Group type: EXPERIMENTAL
Intervention: Bupivacaine (B) alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bupivacaine (B) + 10 mg Fentanyl (F)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bupivacaine (B) + 20 mg Fentanyl (F)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (Bupivacaine alone)
Number of subjects: 45
Study: 15156797

Group type: EXPERIMENTAL
Intervention: Patients with unilateral neglect
Number of subjects: 0
Study: 11305405

Group type: EXPERIMENTAL
Intervention: Gabapentin at 24 to 70 mg/kg/day
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Gabapentin for simple partial seizures
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Gabapentin for complex partial seizures
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Gabapentin for secondarily generalized tonic-clonic seizures
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 237
Study: 9253313

Group type: EXPERIMENTAL
Intervention: Depo-testosterone administered to boys
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens administered to girls
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8494650

Group type: EXPERIMENTAL
Intervention: New formulation of almagate (1.5 g, po)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Alginate + antacid (2.4 g, po)
Number of subjects: 21
Study: 3661479

Group type: EXPERIMENTAL
Intervention: Daily aerobic exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 8
Study: 29951552

Group type: EXPERIMENTAL
Intervention: Adhesive derived from natural latex associated with a light‐emitting diode (LED) circuit (group 1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dressing at home performed by nurses (group 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dressing adhesive derived from natural latex associated with the LED circuit (group 3)
Number of subjects: 15
Study: 27009893

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 2525

Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 2525
Study: 24931249

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Swimming
Number of subjects: 120

Group type: COMPARATOR
Intervention: Powerstriding
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 22430689

Group type: EXPERIMENTAL
Intervention: 17% EDTA followed by 3% NaOCl as root canal irrigant (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MTAD as root canal irrigant (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline as root canal irrigant (Control Group)
Number of subjects: 60
Study: 20660429

Group type: EXPERIMENTAL
Intervention: Combined training (negative viscosity + inertia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inertia training
Number of subjects: 0
Study: 18851776

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 100 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Oxycodone HCl IR 10 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 14699540

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid for 5 days postoperatively
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Clindamycin postoperatively
Number of subjects: 288

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 288
Study: 11735775

Group type: EXPERIMENTAL
Intervention: Transfusion therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 9643210

Group type: EXPERIMENTAL
Intervention: Endekay (urea) chewing gum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluoride chewing gum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trident chewing gum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wrigley's chewing gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sucrose 10% (w/v) rinse (control)
Number of subjects: 20
Study: 8424267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 300 U of rHuEPO per kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 600 U of rHuEPO per kg
Number of subjects: 50
Study: 3818750

Group type: EXPERIMENTAL
Intervention: External fixator
Number of subjects: 58

Group type: COMPARATOR
Intervention: Forearm plaster
Number of subjects: 58
Study: 30987814

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine solution for meatal cleaning before urinary catheterization
Number of subjects: 1642

Group type: COMPARATOR
Intervention: 0.9% normal saline (control phase)
Number of subjects: 1642
Study: 30383074

Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets (Damon System)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional brackets (Roth philosophy)
Number of subjects: 24
Study: 26704029

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 4177

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 4177
Study: 24149007

Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 2582

Group type: COMPARATOR
Intervention: Guideline‐recommended blood pressure lowering
Number of subjects: 2582
Study: 22692171

Group type: EXPERIMENTAL
Intervention: Moxifloxacin and meropenem (1 g every 8 hours of meropenem and 400 mg every 24 hours of moxifloxacin)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Meropenem alone
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Moxifloxacin and meropenem (combination therapy)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Meropenem alone (monotherapy)
Number of subjects: 600
Study: 20808013

Group type: EXPERIMENTAL
Intervention: Continuous infiltration of bupivacaine to the subcutaneous tissue and intra‐articular space for 48 hours, in addition to PCA
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intra‐articular injection of local anaesthetic followed by continuous infiltration of bupivacaine to the subcutaneous tissue and intra‐articular space for 48 hours, in addition to PCA
Number of subjects: 54

Group type: COMPARATOR
Intervention: Patient‐controlled analgesia (PCA) with intravenous morphine for 48 hours
Number of subjects: 54
Study: 17682671

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 32
Study: 15063406

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CMVIG
Number of subjects: 192

Group type: COMPARATOR
Intervention: No anti-CMV therapy (Group 2)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Group 1 (ganciclovir and CMVIG combined)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 192

Group type: COMPARATOR
Intervention: Group 2 (no therapy)
Number of subjects: 192
Study: 11140921

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (up to 300 mg daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 23
Study: 9278797

Group type: EXPERIMENTAL
Intervention: Combined diclofenac 0.1% and gentamicin 0.3% eyedrops (Digen)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gentamicin 0.3% eyedrops
Number of subjects: 90
Study: 7748321

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3729755

Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride (Desyrel) 200 mg/d
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride (Desyrel)
Number of subjects: 27
Study: 30290289

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 8246

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 8246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8246
Study: 27913929

Group type: EXPERIMENTAL
Intervention: Inpatient multimodal pain therapy (MPT) with additional neuromuscular core stability exercises (NCSE), n = 25
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care (SC), n = 23
Number of subjects: 48
Study: 25401406

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 31
Study: 23281263

Group type: COMPARATOR
Intervention: Standard OPEC/OJEC
Number of subjects: 262

Group type: COMPARATOR
Intervention: Rapid COJEC
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Standard OPEC/OJEC or Rapid COJEC
Number of subjects: 262
Study: 21624672

Group type: EXPERIMENTAL
Intervention: EndoButton
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transfix
Number of subjects: 30
Study: 18289163

Group type: EXPERIMENTAL
Intervention: 3 mg of oral melatonin
Number of subjects: 46
Study: 16611949

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control (no Burch colposuspension)
Number of subjects: 322
Study: 12924757

Group type: EXPERIMENTAL
Intervention: EDH of 10,000 ft agl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EDH of 6000 ft agl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EDH of 3000 ft agl
Number of subjects: 30
Study: 10871557

Group type: EXPERIMENTAL
Intervention: Cocoa beverage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Caffeine-containing beverage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water
Number of subjects: 30
Study: 9124665

Group type: EXPERIMENTAL
Intervention: SCOTI device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wee device
Number of subjects: 50
Study: 8459063

Group type: EXPERIMENTAL
Intervention: Home-based bicycle exercise training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study: 30957143

Group type: EXPERIMENTAL
Intervention: Alcoholic chronic liver disease cohort
Number of subjects: 17094

Group type: EXPERIMENTAL
Intervention: Chronic liver disease with HBV or HCV cohort
Number of subjects: 17094
Study: 29921381

Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Mini-incision surgery
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 216
Study: 27100415

Group type: EXPERIMENTAL
Intervention: Peptic ulcer disease (PUD) group
Number of subjects: 27132

Group type: COMPARATOR
Intervention: Non-PUD group (control)
Number of subjects: 27132

Group type: EXPERIMENTAL
Intervention: PUD with proton-pump inhibitors (PPIs) use
Number of subjects: 27132

Group type: COMPARATOR
Intervention: PUD group vs Non-PUD group
Number of subjects: 27132